Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura.
In the pathogenesis of thrombotic thrombocytopenic purpura (TTP), reductions in the enzyme activity of ADAMTS13, which cuts ultralarge von Willebrand multimers, generates shear stress on the microvascular endothelium, leading to platelet aggregation and the formation of a thrombus. ADAMTS13 activity is markedly decreased in typical TTP, but is only mildly reduced in secondary TTP, which concomitantly develops with primary disease. The latter develops with septic disseminated intravascular coagulation (DIC) and often causes organ failure. Recombinant thrombomodulin (rTM) is a drug that is used to treat DIC and may also remit TTP because it improves vascular endothelial dysfunction. Therefore, we herein investigated the efficacy of rTM in patients treated for the pathology of secondary TTP. Patients who were admitted to the Emergency and Critical Care Center of our hospital and met the following conditions were extracted and retrospectively analyzed: hemolytic anemia accompanied by fragmented red blood cells (Hb < 12 g/dL or lower); thrombocytopenia (<100 × 10/μL); and ADAMTS13 activity <50%. Sixteen patients were included and accompanied by Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 or more severe nephropathy and DIC. Eleven and 5 patients treated with and without rTM (the rTM and non-rTM treatment groups, respectively) were compared, and no significant difference was noted in their basic characteristics, such as background disease and severity. No significant difference was observed in survival rates; however, the platelet count, which is an important outcome of treatments for TTP, significantly increased in the rTM treatment group: 3.3 ± 2.6→11.3 ± 14.6 versus 3.5 ± 3.7→5.7 ± 3.9 (×1000/μL) (P = 0.034). Thrombotic thrombocytopenic purpura originally requires invasive treatments and its prognosis is not favorable. Blood thrombomodulin levels also markedly increase due to vascular endothelial dysfunction, whereas rTM alleviates vascular endothelial dysfunction in TTP patients with high blood TM levels, suggesting the importance of administering rTM. Thus, rTM may be effective for secondary TTP and may be adopted as adjuvant therapy.
Department of Emergency and Critical Care Medicine, Hitachi General Hospital, Hitachi, Ibaraki Department of Emergency and General Medicine, JR General Hospital, Sibuya-ku, Tokyo Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Kensuke
K
Nakamura
Ryota
R
Inokuchi
Takahiro
T
Hiruma
Kazuma
K
Ohshima
Tomohiro
T
Sonoo
Kurato
K
Tokunaga
Kent
K
Doi
Susumu
S
Nakajima
D000071120:ADAMTS13 Protein / Q000097:blood*; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy* / Q000201:enzymology; D011994:Recombinant Proteins; D012189:Retrospective Studies; D018180:Thrombomodulin / Q000008:administration & dosage*; D016896:Treatment Outcome
D011994:Recombinant Proteins; D018180:Thrombomodulin; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human